Advanced search
Publication Cover
Expert Review of Vaccines Volume 3, 2004 - Issue 3
Submit an article Journal homepage
213
Views
30
CrossRef citations to date
0
Altmetric
Miscellaneous

A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine

Pierre Van Damme University of Antwerp, Campus 3 Eiken, Universiteitsplein 1, B-2610, Wilrijk, Belgium. [email protected]
&
Koen Van Herck University of Antwerp, Campus 3 Eiken, Universiteitsplein 1, B-2610, Wilrijk, Belgium
Pages 249-267 | Published online: 09 Jan 2014

References

  • World Health Organization. Hepatitis A vaccines. WHO position paper. Wkly EpidemioL Rec. 75,38–42 (2000).
  • Hadler SC. Global impact of hepatitis A virus infection; changing patterns. In: Viral Hepatitis and Liver Diseases. Hollinger FB, Lemon SM, Margolis HS (Eds), Williams & Wilkins, MD, USA, 14–20 (1991).
  • Koff RS. Hepatitis A. Lancet 351, 1643–1648 (1998).
  • Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics109(5), 839–845 (2002).
  • Hadler SC, Hollinger FB, Lemon SM, Margolis H. Global impact of hepatitis A virus infection changing patterns. In: Viral Hepatitis, and Liver Disease: Contemporary Issues and Future Prospects. Hollinger FB, Lemon SM, Margolis HS (Eds). Williams & Wilkins, TX, USA, 14–20 (1991).
  • Joussemet M, Depaquit J, Nicand E et al. Fall in the seroprevalence of hepatitis A in French youth. GastroenteroL Clin. Biol. 23(4), 447–451 (1999).
  • FrOsner GG, Papaevangelou G, Butler R et al. Antibody against hepatitis A in seven European countries. Comparison of prevalence data in different age groups. Am. EpidemioL 110,63–69 (1979).
  • Tilzey A, Banatvala JE. Hepatitis A: changing prevalence and possible vaccines. Br. Med. J. 302,1551–1552 (1991).
  • Rooney CF, Rodrigues L. Hepatitis A immunization. Br. Med. J. 303,414 (1991).
  • Rarzaga NG. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine 18, S61—S64 (2000).
  • Poovorawan Y, Chatchatee P, Chongsrisawat V. Epidemiology and prophylaxis of viral hepatitis: a global perspective. J. GastroenteroL HepatoL 17(Suppl.), S155—S166 (2002).
  • Chatchatee P, Chongsrisawat V, Theamboonlers A, Poovorawan Y. Declining hepatitis A seroprevalence among medical students in Bangkok, Thailand, 1981–2001. Asian Pac. J Allergy ImmunoL 20(1), 53–56 (2002).
  • Kane M. Global program for control of hepatitis B infection. Vaccine 13\(Suppl. 1), S47—S49 (1995).
  • World Health Organization. Expanded program on Immunization. Global Advisory Group — Part 1. Wkly EpidemioL Rec. 67,11-15 (1992).
  • Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunization programs. Br. Med. 1314(7086), 1033–1036 (1997).
  • Loscher T, Keystone JS, Steffen R. Vaccination of travellers against hepatitis A and B. J Tray. Med. 6(2), 107–114 (1999).
  • Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep. 48 (RR-12), 1–37 (1999).
  • •Updates ACIP 1996 recommendations on the prevention of hepatitis A through immunization and includes data on epidemiology of the disease and effectiveness of vaccination programs.
  • Innis BL, Snitbhan R, Kunasol P etal. Protection against hepatitis A by an inactivated vaccine. JAMA 271,1328–1334 (1994).
  • Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl. J Med. 327(7), 453–457 (1991).
  • Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15(11), 1209–1213 (1997).
  • Zamir C, Rishpon S, Zamir D etal. Control of a community-wide outbreak of hepatitis A by mass vaccination with inactivated hepatitis A vaccine. Eur. I Clin. Microbiol Infect. Dis. 20,185–187 (2001).
  • Hadler SC, Francis DP, Maynard JE et al Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl. J. Med. 315(4), 210–214 (1986).
  • Chen HL, Chang MH, Ni YH et al. Seroepidemiology of hepatitis B virus infection in children. Ten years of mass vaccination in Taiwan. JAMA 276, 906–908 (1996).
  • Lin HH, Wang L-Y, Hu C-T et al Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med. Virol 69,471–474 (2003).
  • Ni YH, Chang MH, Huang LM et al Hepatitis B virus infection in children and adolescents in a hyperepidemic area: 15 years after mass hepatitis B vaccination. Ann. Intern. Med. 135,796-800 (2001).
  • Poovorawan Y, Sanpavat S, Pongpunlert W etal. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 261, 3278–3281 (1989).
  • Le C. Control of hepatitis A infection in the US. West. J Med. 170(6), 324 (1999).
  • Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med. Virol 65(1), 6–13 (2001).
  • •Long-term immunogenicity and safety results with Twinrix.
  • Thoelen S, Van Damme P, Leentvaar-Kuypers A et al The first combined vaccine against hepatitis A and B: an overview. Vaccine 17,1657–1662 (1999).
  • ••Summary of European pivotal clinicalresults with Twirnix in adults.
  • Wagstaff AJ, Balfour JA. Combination of hepatitis A — hepatitis B vaccine. Biodrugs 8(3), 235–239 (1997).
  • Knoll A, Hottenträger B, Kainz J, Bretschneider B, Jilg W Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine 18(19), 2029–2032 (2000).
  • Van Damme P, Van der Wielen M. Combining hepatitis A and B vaccination in children and adolescents. Vaccine 19, 2407–2412 (2001).
  • ••Summary of clinical trial results withTwirnix in children and adolescents.
  • Steffen R. Immunization against hepatitis A and hepatitis B infections. J Travel Med. 8\(Suppl. 1), S9—S16 (2001).
  • World Health Organization. International Travel and Health, Vaccination requirements and health advice, 2001. World Health Organization, Geneva (2001).
  • National Advisory Committee on Immunization. Canadian Immunization Guide. 5th Edition. Ottawa, Department of National Health and Welfare, 215 (1998).
  • Steffen R, Castelli F, Nothdurft H et al Travel health knowledge, attitudes and practice among European travelers. Proc. 8th Con! Intl Soc. Tray Med., NY, USA. 103 (2003).
  • Van Herck K, Zuckerman J, Castelli F et al. Travelers' knowledge, attitudes and practices on prevention of infectious diseases: results from a pilot study. J Tray Med. 10,75–78 (2003).
  • Van Herck K, Castelli F, Zuckerman J et al. Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Tray Med. 11, 3–8 (2004).
  • Zuckerman, Steffen R. Risks of hepatitis B in travelers as compared to immunization status. J. Tray Med. 7(4), 170–174 (2000).
  • Zwar N. Hepatitis risk and vaccination among Australian travellers overseas. Med. J. Aust. 178,469–470 (2003).
  • Zuckerman JN. Vaccination priorities in travel. Biodrugs 17 (Suppl. 1), 1–6 (2003).
  • De Serres G, Duval B, Shadmani R et al Ineffectiveness of the current strategy to prevent hepatitis A in travelers. J. Tray Med. 9 (1), 10–16 (2002).
  • Steffen R. Despite good tools, we do not effectively reduce travelers' hepatitis A. J. Tray Med. 9(1), 1–2 (2002).
  • Centers for Disease Control and Prevention. Update on adult immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly Rep. (RR12) 40,1–94 (1991).
  • Gibas A, Blewett K, Schoenfeld DA, Dienstag JL. Prevalence and incidence of viral hepatitis in health workers in the pre-hepatitis B vaccination era. Am. J. Epidemiol 136,603–610 (1992).
  • Gunson RN, Shouval D, Roggendorf M et al. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J. Clin. Virol 27(3), 213–30 (2003).
  • Occupational Safety and Health Administration (OSHA). Enforcement procedures for the occupational exposure to bloodborne pathogens. Directive Number CPL 2–2.69. OSHA Instruction (2001).
  • Mahoney FJ, Stewart K, Hu H, Coleman P, Alter M. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch. Intern. Med. 157(22), 2601–2605 (1997).
  • Zimmerman RK, Middleton DB, Smith NJ. Vaccines for persons at high risk due to medical conditions, occupation, environment or lifestyle, 2003. J. Fam. Frac. 52(1), S22—S35 (2003).
  • Averhoff FM, Moyer LA, Woodruff BA et al. Occupational exposures and risk of hepatitis B virus infection among public safety workers. I Occup. Environ. Med. 44(6), 591–596 (2002).
  • Petrosillo N, Raffaele B, Martini L et al. A nosocomial and occupational cluster of hepatitis A virus infection in a pediatric ward. Infect. Control Hosp. Epidemiol 23(6), 343–345 (2002).
  • Doebbeling BN, Li N, Wenzel RP. An outbreak of hepatitis A among health care workers: risk factors for transmission. Am. J Public Health 83(12), 1679–1684 (1993).
  • Abb J. Prevalence of hepatitis A virus antibodies in hospital personnel. Gesundheidswesen 56(7), 377–379 (1994).
  • Vandersmissen G, Moens G, Jacques P, Vranckx R, Wollants W Is there a higher risk for hepatitis A in Flemish health care workers? A seroprevalence study. Arch. Public Health 59,137–149 (2001).
  • Kessler ER. Vaccine-preventable diseases in health care. Occup. Med. 12(4), 731–739 (1997).
  • Domart M, Mlika-Cabanne N, Henzel D et al. Hepatitis A among health workers in Paris hospitals. J. Med. Virol 58,321–324 (1999).
  • Van Damme P. Occupationally acquired hepatitis A infection. Viral Hepatitis 3(2) 12–13 (1995).
  • Vranckx R, Jacques P, Moens G. Prevalence of hepatitis A antibodies in a large sample of Belgian health care workers. Infection (4–5), 256–258 (1999).
  • Jacques P, Moens G, Van Damme P et al. Increased risk of hepatitis A among female day-nursery workers in Belgium. Vaccine 12(10), 958 (1994).
  • Hofmann F, Wehrle G, Berthold H, Koster D. Hepatitis A as an occupational hazard. Vaccine 10\(Suppl. 1), S82—S84 (1992).
  • Franco E, Giambi C, Ialacci R et al. Risk groups for hepatitis A virus infection. Vaccine 21,2224–2233 (2003).
  • Zimmerman RK, Middleton DB and Smith NJ. Vaccines for persons at high risk due to medical conditions, occupation, environment, or lifestyle. J. Fam. Prac. 52(1), 22–35 (2003).
  • Van Damme P, Meheus A, Vranckx R, Safary A, André E Vaccination of mentally handicapped with a recombinant hepatitis B vaccine: 3 year follow up. In: Progress in Hepatitis B Immunization. Coursaget P, MJ Tong (Eds), Colloque INSERM/John Libbey Eurotext Ltd, Paris, France, 147–156 (1990).
  • Pramoolsinsap CJ. Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or Hepatitis C virus-related chronic liver diseases in Thailand. Viral Hepatitis 7\(Suppl. 1), 11–12 (2000).
  • Keefe E. Hepatitis A in patients with chronic liver disease — severity of illness and prevention with vaccination. J Viral Hepatitis 7\(Suppl. 1), 15–17 (2000).
  • Keeffe EB. Vaccination against hepatitis A and B in chronic liver disease. Viral Hep. Rev 5(2), 77–88 (1999).
  • Bell BP. Hepatitis A and B vaccination of patients with chronic liver disease. Acta Gastroenterol Belg. 63(4), 359–363 (2000).
  • Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep. 45 (RR-15), 1–30 (1996).
  • Chalasani N, Smallwood G, Halcomb J et al Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transplant. Surg. 4(2), 128–132 (1998).
  • Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of Hepatitis A vaccination in decompensated cirrhotic patients. Hepatology34(1), 28–31 (2001).
  • Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S. Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Z. Gastroenterol 41,983–990 (2003).
  • Cotter SM, Sansom S, Long T et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. I Int: Dis. 187,1235–1240 (2003).
  • MacKellar DA, Valleroy LA, Secura GM et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Ain. J. Public Health 91(6), 965–971 (2001).
  • Mast EE, Williams IT, Alter MJ, Margolis HS. Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Vaccine16(Suppl.), S27—S29 (1998).
  • Dufour A, Remis RS, Michel A eta] Factors associated with hepatitis B vaccination among men having sexual relations with men in Montreal, Quebec, Canada. Sex. Transm. Dis. 26,317–324 (1999).
  • Goldstein ST, Alter MJ, Williams IT et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. J Inf. Dis. 185,713-719 (2002).
  • Centers for Disease Control and Prevention. Undervaccination for hepatitis B among young men who have sex with men. San Francisco and Berkeley, California, 1992–1993. Morb. Mortal. Wkly Rep. 45,2157 (1996).
  • Remis RS, Dufour A, Alary M et al Association of hepatitis B virus infection with other sexually transmitted infections in homosexual men. Omega Study Group. Am. J Public Health 90(10), 1570–1574 (2000).
  • Yee LJ, Rhodes SD. Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned? Sex. Transm. Infec. 78,374–377 (2002).
  • Diamond C, Thiede H, Perdue T et al. Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination. Sex. Transm. Dis. 30 (5), 425–432 (2003).
  • Centers for Disease Control and Prevention (CDC). National hepatitis prevention strategy. CDC 2–19 (2001).
  • Koff RS. Hepatitis vaccines: recent advances. Int. J. Parasitol 33,517–523 (2003).
  • Dagan R, Amir J, Mijalovsky A et al Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J. 19,1045–1052 (2000).
  • Germinario C, Lopalco PL, Chicanna M, Da Villa G. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 18 (Suppl. 1), S83—S85 (2000).
  • Dominguez A, Salleras L, Carmona G, Batalla J. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 21(7-8), 698–701 (2003).
  • Dagan R. Update from Israel, the first country to adopt hepatitis A universal immunization program. Proc. 3rd World Congress Pediatr. Infect. Dis., Santiago, Chile, 12 (2002).
  • Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A. Simultaneous passive and active immunization against hepatitis A. Vaccine 10\(Suppl. 1), S138—S141 (1992).
  • Zaaijer A, Leentvaar-Kuijpers A, Rotrnan H, Lelie PN. Hepatitis A antibody titers after infection and immunization: implications for passive and active immunization. J Med. Virol 40,22–27 (1993).
  • Centers for Disease Control and Prevention. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination-recommendations of the Immunization Practices Advisory Committee (ACIP). Anonymous. Morb. Mortal. Wkly Rep. 40(RR13), 1–25 (1991).
  • World Health Organization. Informal consultation on quadrivalent diphtheria—tetanus—pertussis—hepatitis B vaccine. WHO Geneva 1–12 (1992).
  • World Health Organization. Perspectives for vaccination with DTP-HB vaccines. Anonymous. Global Perspect. Hep. 4(1), 1–10 (1993).
  • Frey S, Dagan R, Ashur Y et al Interference of antibody production of hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect. Dis. 181, 2018–2022 (1999).
  • Kallinowski B, Knoll A, Lindner E eta] Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/hepatitis B vaccine during primary immunization course? Vaccine 19,16–22 (2000).
  • Abraham B, Parenti D. Antibody production in response to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect. Dis. 182, 1005 (2000).
  • Joines RW, Blatter M, Abraham B et al A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (HavrixTm and EngerixTm-B) in adults. Vaccine 19, 4710–4719 (2001).
  • ••US study in 773 subjects comparing theimmunogenicity of Twinrix with the immunogenicity of simultaneous administration of Havrix and Engerix-B.
  • Ambrosch F, Wiedermann G, Andre FE et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med. Viral. 44, 452–456 (1994).
  • Rendi-Wagner P, Kundi M, Stemberger H et al. Antibody response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 19, 2055–2060 (2001).
  • ••Study in 1874 subjects comparing theimmunogenicity of Twinrbc with the immunogenicity of simultaneous administration of Havrbc and Engerix-B.
  • Czeschinski PA, Binding N and Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 18,1074–1080 (2000).
  • Tsai I-J, Chang M-W, Chen H-L et al Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults. Vaccine 19(4-5), 437–441 (2001).
  • Thompson SC, Norris M. Immunogenicity and reactogenicity of a combined hepatitis A-Hepatitis B vaccine in adolescents. Int. Infect. Dis. 2(4), 193–196 (1998).
  • Van Damme P Unpublished data.
  • West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14, 1019–1027 (1996).
  • Van Herck K, Van Damme P, Thoelen S, Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast derived hepatitis B vaccine: 8 year results. Vaccine 16,1933–1935 (1998).
  • Van Herck K, Van Damme P Inactivated hepatitis A vaccine induced antibodies: follow-up and estimates of long-term persistence. .1. Med. Virol 63,1–7 (2001).
  • Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. I Med. Virol 72(2), 194–196 (2004).
  • Bovier PA, Bock J, Loutan L et al. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. I Med. Virol 68(4), 489–493 (2002).
  • European Consensus Group on Hepatitis B Immunity. Kane M, Banatvala J, Da Villa G et al Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 355,561-565 pooy.
  • ••European Consensus statement: there areno data to support the need for booster vaccination after a successful primary hepatitis B vaccination course.
  • Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli V. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 19,3164-3268 poly.
  • Dentico P, Crovari P, Luigi Lai P et al. Anamnestic response to administration of purified nonadsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term nonprotective antibody titers. Vaccine 20,3725–3730 (2002).
  • Van Damme P, Banatvala J, Fay 0 etal. Hepatitis A booster vaccination: is there a need? Lancet 362,1065–1071 (2003).
  • ••Consensus statement: there is no evidenceto lend support to HAV booster vaccination after a successful primary hepatitis A vaccination course in healthy individuals. in Van Herck K, Renard D, Molenberghs G, Van Damme P Model-based estimates of long-term persistence of vaccine-induced hepatitis A antibodies, Australia, 56-59. 10th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia (2002).
  • Van Herck K, Renard D, Molenberghs G, Van Damme P. Model-based estimates of long-term persistence of vaccine-induced ahepatitis A antibodies, Australia, 56–59. 10th International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia (2002).
  • Wiens BL, Bohidar NR, Pigeon JG et al Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. Med. Virol 49(3), 235–241 (1996).
  • Reutter J, Bart PA, Francioli P, Safary A, Frei PC. Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/hepatitis B vaccination in 242 adult volunteers. J. Viral Hepatitis 205–211 (1998).
  • Averhoff F, Mahoney F, Coleman P et al. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am. J. Prev. Med. 15, 1–8 (1998).
  • Reuman PD, Kubilis P, Hurni W, Brown L, Nalin D. The effect of age and weight on the response to formalin inactivated alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 15,1157–1161 (1997).
  • Bock HL, Kruppenbacher J, Sanger R et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch. Intern. Med. 156, 2226–2231 (1996).
  • De Rave S, Heijtink RA, Bakker-Bendik M, Boot J, Schalm SW Immonogenicity of standard and low dose vaccination using yeast-derived recombinant B surface antigen in elderly volunteers. Vaccine 12, 532–534 (1994).
  • Stoffel M, Lievens M, Dieussaert I, Martin I, André E Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rey Vaccines 2(1), 9–14 (2003).
  • Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin. Inf. Dis. 35,1368-1375 (2002).
  • Young MD, Schneider DL, Zuckerman AJ et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology34, 372–376 (2001).
  • Shaw FE, Guess HA, Roets JM et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 7(5), 425–430 (1989).
  • Briem H and Safary A. Immungenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. .1. Med. Virol 44,443–445 (1994).
  • Keystone J, Parsons J, Anstey R. Reactogenicity and immunogenicity of a combined vaccine against hepatitis A and B in older adults. Proc. 9th Triennal Intl Symp. Viral Hep. Liver Dis., Rome, Italy, (1996).
  • Wolters B, Junge U, Dziuba S and Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21,3626–3628 (2003).
  • Grosheide P, Van Damme P Prevention and control of hepatitis B in the community In: Communicable Diseases Series 1. Hallauer J, Kane M, McCloy E, Meheus A, Roure C (Eds), Viral Hepatitis Prevention Board Secretariat, Belgium. 64 (1996).
  • Safary A and André E Over a decade of experience with yeast recombinant hepatitis B vaccine. Vaccine 18(1-2), 57–62 (1999).
  • •Review of 10 years of experience with Engerix-B.
  • André F, Van Damme P, Safary A and Banatvala J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev Vaccinesl, 9–23 (2002).
  • •Review of 10 years of experience with Havrbc.
  • Van Damme P, Van Herck K and Van der Wielen M. Combined hepatitis A and B vaccine in elderly. Vaccine 22(3-4), 303–304 (2003).
  • Nothdurft HD, Aurniftler H, Aurniftler R et al A breakthrough case of hepatitis A disease following a full vaccination schedule of three doses of a combined hepatitis A and B vaccine. Vaccine 22(5-6), 592–593 (2004).
  • Diaz-Mitoma, F, Law B, Parsons J. A combined vaccine against hepatitis A and B in children and adolescents. Pediatr. Infect. Dis. J 18,109–114 (1999).
  • Van Damme P, Vellinga A. Epidemiology of hepatitis B and C in Europe. Acta Castro-Enterologica Belg. 61(2), 175–182 (1998).
  • Van Herck K, Van Damme P, Collard F, Thoelen S. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11–18 years. Scand. I Gastroenterol 34(12) 1236–1240 (1999).
  • Van der Wielen M, Van Damme P, Collard E A two-dose schedule for combined hepatitis A and hepatitis B vaccination in children aged one to eleven years. Pediatr. Infect. Dis. J. 19, 848–53 (2000).
  • Burgess MA, Rodger AJ, Waite SHA, Collard E Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomized study. Vaccine 19,4835–4841 (2001).
  • Levie K, Beran J, Collard F, Nguyen C. Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years. Vaccine 20,2579–2584 (2002).
  • •Comparative study Ambirix versus Twinrix pediatric.
  • Roberton D, Nolan T, Sokal E etal. Two-dose combined vaccine against hepatitis A and B in children. Proce.43rd Interscience Con! Antimicrob. Agents Chemother. KAA 0, Chicago, 294 (2003).
  • Beran J. Combined two-dose hepatitis A and B vaccine (AmBirix). Drugs 63(2), 214–215 (2003).
  • Van Damme P, Cramm M, Van Gompel A et al. Analysis of travellers profile on Belgium. Proceedings of the 3rd Conference in International Travel Medicine, Paris, France, P267 (1993).
  • Nothdurft HD, Dietrich M, Zuckerman J et al. Rapid protection against hepatitis A and B. Vaccine 20,1157–1162 (2002).
  • Van Damme P, Lievens M, Stoffel M et al. Rapid seroconversion rates after first dose of an inactivated hepatitis A vaccine (HavrixTm 1440): results of a retrospective analysis. Travel & Epidemics: 3rd European Conference on Travel Medicine, Florence, Italy, 210 (2002).
  • Connor BA, Van Herck K, Van Damme Rapid protection and vaccination against hepatitis A for travellers. Biodrugs17\(Suppl. 1), 19–21 (2003).
  • Nothdurft HD, Dietrich M, Zuckerman J et al. Rapid protection against hepatitis A and B using an accelerated vaccination schedule. Comparison of combined vaccine, Twinrix®, with separate vaccines. Biodrugs 17\(Suppl. 1), 15–18 (2003).
  • Proell S, Maiwald H, Nothdurft HD et al Combined vaccination against hepatitis A, hepatitis B and typhoid fever: safety, reactogenicity and immunogenicity. Travel Med. 9(3), 122–126 (2002).
  • American College of Obstetricians and Gynecologists. Immunization during pregnancy. ACOG Committee Opinion No. 282. Obstet. Gynecol 101,207–212 (2003).
  • MacIntyre CR, Burgess MA, Hull B, McIntyre PB. Hepatitis A vaccination options for Australia. J Paediatr. Child Health 39,83–87 (2003).
  • Green MS, Aharonowitz G, Shohat T et al. Isr. Med. Assoc. 3(5), 347–351 (2001).
  • Lopalco PL, Salleras L, Barbuti S et al Hepatitis A and B in children and adolescents — what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 19(4–5), 470–474 (2000).
  • Steffen R, Banos A, de Bernardis C. Vaccination priorities. Int. J Antimicrob. Agents 21,175–180 (2003).
  • Theamboonlers A, Jantaradsamee P, Chatchatee P etal. Molecular characterization of hepatitis-A-virus infections, in the context of two outbreaks in southern Thailand. Ann. Trop. Med. Parasitol 96(7), 727–34 (2002).
  • Sohn YM, Rho HO, Park MS etal. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med. J 41 (1), 34–39 (2000).
  • Sinlaparatsamee S, Nuniem J, Kankao J et al. An outbreak of hepatitis A in school children at Nakhon Si Thammarat, southern Thailand. Southeast Asian J. Trop. Med. Public Health. 26(1), 104–108 (1995).
  • Poonawagul U, Warintrawat S, Snitbhan R et al Outbreak of hepatitis A in a college traced to contaminated water reservoir in cafeteria. Southeast Asian J. 71-op. Med. Public Health 26(4), 705–708 (1995).
  • Jutavijittum P, Jiviriyawat Y, Jiviriyawat W et al Present epidemiological pattern of antibody to hepatitis a virus among Chiang Mai children, Northern Thailand. Southeast Asian J. Trop. Med. Public Health 33 (2), 268–271 (2002).
  • Poovorawan Y, Theamboonlers A, Sinlaparatsamee S etal. Increasing susceptibility to HAV among members of the young generation in Thailand. Asian Pac. J. Allergy Immunol 18(4), 249–53 (2000).

Websites

  • Tufenkeji H. Hepatitis A shifting epidemiology in the Middle East and Africa. Vaccine 18 (Sunni. 1), S65—S67 (2000).
  • World Health Organization. Hepatitis B fact sheet, 2002 www.who.int/vaccines/en/hepatitisb.shtml. Accessed May, 2004.
  • World Health Organization. Global progress toward universal childhood hepatitis B vaccination, 2003. Weekly Epidemiological Record 42,366-370 (2003). www.who.int/wer/2003/wer7842/en/ Accessed May, 2004.
  • Global Alliance for Vaccines and Immunization. GAVI Milestones, 2003. www.vaccinealliance.org/home/General_In formation/About_alliance/Background/mil estones.php?PHPSESSID = ba316d838f5fbdce959dfd874170d4bb Accessed May, 2004.
  • World Health Organization. Hepatitis A fact sheet (2002). www.who.int/vaccines/en/hepatitisa.shtml Accessed May, 2004)
  • Centers for Disease Control and Prevention. National hepatitis C prevention strategy (2001). www.cdc.gov/ncidod/diseases/hepatitis/c/p1 an/index.htm Accessed May, 2004.
  • Gay and Lesbian Medical Association. www.glma.org/hepatitis Accessed February, 2004.
  • www.cdc.gov/ncidod/diseases/hepatitis/slides Accessed May, 2004.
  • World Health Organization. Hepatitis B. WHO Fact Sheet n0204 (2000). www.who.int/inf-fs/en/fact204.html Accessed May, 2004.
  • GlaxoSmith Kline vaccines www.worldwidevaccines.com.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.